Compounds of formula (I):
wherein
R
1
represents optionally substituted C
4-12
alkyl, optionally substituted C
2-6
alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl;
Z represents a bond, CH
2
, O, S, SO, SO
2
, NR
4
, OCR
4
R
5
, CR
4
R
5
O, or Z, R
1
and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring;
X represents COR
3
or N(OR
8
)COR
9
;
R
2
represents SO
2
R
10
or SO
2
NR
10
R
11
;
R
3
represents OR
6
, NR
6
R
7
or NR
6
OH;
R
4
and R
5
each independently represents H, C
1-6
alkyl or C
1-4
alkylaryl;
R
6
and R
7
each independently represents H, C
1-6
alkyl, or C
1-6
alkyl substituted with one or more heteroaryl groups, or R
6
and R
7
together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N;
R
8
and R
9
each independently represents H or C
1-6
alkyl;
R
10
and R
11
each independently represents H or C
1-6
alkyl; and and physiologically functional derivatives thereof, with the exception of N-(ethoxycarbonyl)-N-[4-(1H-tetrazol-1-yl)phenyl]glycine, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metalloproteinase enzymes (MMPs) are described.
化学式为(I)的化合物:
其中,
R1表示可选择取代的C4-12烷基,可选择取代的C2-6烷基芳基,或可选择取代的5-或6-成员芳基或杂芳基;
Z表示键,
CH2,O,S,SO,SO2,NR4,OCR4R5,CR4R5O或Z;
R1和Q共同形成可选择取代的融合
三环基团;
Q表示可选择取代的5-或6-成员芳基或杂芳基环;
X表示COR3或N(OR8)COR9;
R2表示SO2R10或SO2NR10R11;
R3表示OR6,NR6R7或NR6OH;
R4和R5各自独立地表示H,C1-6烷基或C1-4烷基芳基;
R6和R7各自独立地表示H,C1-6烷基,或带有一种或多种杂芳基基团的C1-6烷基,或R6和R7与它们所连接的氮原子一起形成一个可选择包括1个或多个进一步的杂原子(从O,S和N中选择)的5-或6-成员环;
R8和R9各自独立地表示H或C1-6烷基;
R10和R11各自独立地表示H或C1-6烷基;
以及其生理功能衍
生物,但不包括N-(乙氧羰基)-N-[4-(
1H-四唑-1-基)苯基]甘
氨酸,描述了它们的制备过程,包含它们的制药配方以及它们作为基质
金属
蛋白酶酶(MMPs)
抑制剂的用途。